^
Association details:
| Biomarker: | HRD + BRCA2 mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.
Published date:
05/25/2023
Excerpt:
Results suggest that long-term PFS in pts treated with niraparib may be associated with BRCA/HRd biomarker status, FIGO stage, primary tumor site, and number of baseline non-target lesions.
DOI:
10.1200/JCO.2023.41.16_suppl.5589
Trial ID:
